SIMCERE PHARMA Receives NMPA Approval for Clinical Trial of SIM0689, a Dual-Target Antibody

Stock News06-12

SIMCERE PHARMA (HKEX: 02096) has announced that its independently developed bispecific antibody, SIM0689, targeting PD-1 and VEGF, has received a drug clinical trial approval notice from China's National Medical Products Administration (NMPA). The trial is intended to be conducted for advanced solid tumors.

SIM0689 is a bispecific antibody that simultaneously targets specific epitopes of the programmed death receptor-1 (PD-1) and vascular endothelial growth factor (VEGF). It exerts potent anti-tumor activity by relieving tumor cell immune suppression and inhibiting angiogenesis.

In various humanized mouse efficacy models, SIM0689 demonstrated superior anti-tumor efficacy even at low doses. Its overall pharmacological effect was significantly better than that of similar molecules, suggesting it has broad application prospects in various types of solid tumors.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116728399?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-12 21:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116728399","market":"sg","top_or_hot":-1,"title":"SIMCERE PHARMA Receives NMPA Approval for Clinical Trial of SIM0689, a Dual-Target Antibody","media":"Stock News","content":"<p>SIMCERE PHARMA (HKEX: 02096) has announced that its independently developed bispecific antibody, SIM0689, targeting PD-1 and VEGF, has received a drug clinical trial approval notice from China's National Medical Products Administration (NMPA). The trial is intended to be conducted for advanced solid tumors.<br><br>SIM0689 is a bispecific antibody that simultaneously targets specific epitopes of the programmed death receptor-1 (PD-1) and vascular endothelial growth factor (VEGF). It exerts potent anti-tumor activity by relieving tumor cell immune suppression and inhibiting angiogenesis.<br><br>In various humanized mouse efficacy models, SIM0689 demonstrated superior anti-tumor efficacy even at low doses. Its overall pharmacological effect was significantly better than that of similar molecules, suggesting it has broad application prospects in various types of solid tumors.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SIMCERE PHARMA Receives NMPA Approval for Clinical Trial of SIM0689, a Dual-Target Antibody</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSIMCERE PHARMA Receives NMPA Approval for Clinical Trial of SIM0689, a Dual-Target Antibody\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-12 21:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SIMCERE PHARMA (HKEX: 02096) has announced that its independently developed bispecific antibody, SIM0689, targeting PD-1 and VEGF, has received a drug clinical trial approval notice from China's National Medical Products Administration (NMPA). The trial is intended to be conducted for advanced solid tumors.<br><br>SIM0689 is a bispecific antibody that simultaneously targets specific epitopes of the programmed death receptor-1 (PD-1) and vascular endothelial growth factor (VEGF). It exerts potent anti-tumor activity by relieving tumor cell immune suppression and inhibiting angiogenesis.<br><br>In various humanized mouse efficacy models, SIM0689 demonstrated superior anti-tumor efficacy even at low doses. Its overall pharmacological effect was significantly better than that of similar molecules, suggesting it has broad application prospects in various types of solid tumors.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1169590202.USD","symbol_name":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","start_time":0,"source_url":"","article_id":"1116728399","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116728399","pubTimestamp":1781269818,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SIMCERE PHARMA (HKEX: 02096) has announced that its independently developed bispecific antibody, SIM0689, targeting PD-1 and VEGF, has received a drug clinical trial approval notice from China's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK1191":"制药","02096":"先声药业","BK4023":"应用软件","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","PD":"PagerDuty, Inc.","BK1583":"高瓴概念"},"translate_title":"先声药业双靶点抗体SIM0689获NMPA临床试验批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PD":1,"02096":1},"content_text":"SIMCERE PHARMA (HKEX: 02096) has announced that its independently developed bispecific antibody, SIM0689, targeting PD-1 and VEGF, has received a drug clinical trial approval notice from China's National Medical Products Administration (NMPA). The trial is intended to be conducted for advanced solid tumors.SIM0689 is a bispecific antibody that simultaneously targets specific epitopes of the programmed death receptor-1 (PD-1) and vascular endothelial growth factor (VEGF). It exerts potent anti-tumor activity by relieving tumor cell immune suppression and inhibiting angiogenesis.In various humanized mouse efficacy models, SIM0689 demonstrated superior anti-tumor efficacy even at low doses. Its overall pharmacological effect was significantly better than that of similar molecules, suggesting it has broad application prospects in various types of solid tumors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116728399","isCrawlerRequest":true}